期刊
CANCER RESEARCH
卷 74, 期 16, 页码 4329-4340出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-14-0093
关键词
-
类别
资金
- DOD award [W81XWH-09-1-0446]
- Cellular, Biochemical and Molecular Sciences training program [5T32GM008554]
- Cancer Center Support Grant [P30 CA068485]
- National Center for Advancing Translational Sciences [2 UL1 TR000445-06, UL1 RR024975-01]
- [R01 CA157781]
IL4, a cytokine produced mainly by immune cells, may promote the growth of epithelial tumors by mediating increased proliferation and survival. Here, we show that the type II IL4 receptor (IL4R) is expressed and activated in human breast cancer and mouse models of breast cancer. In metastatic mouse breast cancer cells, RNAi-mediated silencing of IL4R alpha, a component of the IL4R, was sufficient to attenuate growth at metastatic sites. Similar results were obtained with control tumor cells in IL4-deficient mice. Decreased metastatic capacity of IL4R alpha knockdown cells was attributed, in part, to reductions in proliferation and survival of breast cancer cells. In addition, we observed an overall increase in immune infiltrates within IL4R alpha knockdown tumors, indicating that enhanced clearance of knockdown tumor cells could also contribute to the reduction in knockdown tumor size. Pharmacologic investigations suggested that IL4-induced cancer cell colonization was mediated, in part, by activation of Erk1/2, Akt, and mTOR. Reduced levels of pAkt and pErk1/2 in IL4R alpha knockdown tumor metastases were associated with limited outgrowth, supporting roles for Akt and Erk activation in mediating the tumor-promoting effects of IL4R alpha. Collectively, our results offer a preclinical proof-of-concept for targeting IL4/IL4R alpha signaling as a therapeutic strategy to limit breast cancer metastasis. (C) 2014 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据